BI-1347
≥99%
- Product Code: 57595
CAS:
2163056-91-3
| Molecular Weight: | 356.42 g./mol | Molecular Formula: | C₂₂H₂₀N₄O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
BI-1347 is primarily used in the field of oncology research as a potent and selective inhibitor of CDK8 (Cyclin-Dependent Kinase 8). Its application focuses on studying the role of CDK8 in cancer progression and tumor growth. Researchers utilize BI-1347 to explore its potential in disrupting cancer cell signaling pathways, particularly those involving the Wnt/β-catenin and STAT1 pathways, which are often dysregulated in various cancers. This compound is also employed in preclinical studies to evaluate its efficacy as a therapeutic agent in treating cancers such as colorectal cancer, acute myeloid leukemia, and other malignancies where CDK8 plays a critical role. Additionally, BI-1347 aids in understanding the mechanisms of drug resistance and identifying biomarkers for targeted cancer therapies.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | Beige-yellow crystals |
| PURITY | 98.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $226.82 |
+
-
|
| 0.010 | 10-20 days | $362.74 |
+
-
|
BI-1347
BI-1347 is primarily used in the field of oncology research as a potent and selective inhibitor of CDK8 (Cyclin-Dependent Kinase 8). Its application focuses on studying the role of CDK8 in cancer progression and tumor growth. Researchers utilize BI-1347 to explore its potential in disrupting cancer cell signaling pathways, particularly those involving the Wnt/β-catenin and STAT1 pathways, which are often dysregulated in various cancers. This compound is also employed in preclinical studies to evaluate its efficacy as a therapeutic agent in treating cancers such as colorectal cancer, acute myeloid leukemia, and other malignancies where CDK8 plays a critical role. Additionally, BI-1347 aids in understanding the mechanisms of drug resistance and identifying biomarkers for targeted cancer therapies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :